Optimizing treatment success in multiple sclerosis

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

(2016) Ludwig Kappos et al.   Multiple Sclerosis Journal

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

(2016) Ludwig Kappos et al.   Multiple Sclerosis Journal

The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice

(2015) Tjalf Ziemssen et al.   BMC Neurology

Treating relapsing–remitting multiple sclerosis: therapy effects on brain atrophy

(2015) Angela Vidal-Jordana et al.   JOURNAL OF NEUROLOGY

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

(2015) D. H. Miller et al.   NEUROLOGY

Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial

(2015) L. Kappos et al.   NEUROLOGY

Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort

(2015) Dalia L. Rotstein et al.   JAMA Neurology

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

(2015) Gavin Giovannoni et al.   Multiple Sclerosis and Related Disorders

Optimizing therapy early in multiple sclerosis: An evidence-based view

(2015) Tjalf Ziemssen et al.   Multiple Sclerosis and Related Disorders

Clinical Relevance of Brain Volume Measures in Multiple Sclerosis

(2014) Nicola De Stefano et al.   CNS DRUGS

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study

(2014) Douglas L. Arnold et al.   JOURNAL OF NEUROLOGY

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

(2014) T. L. Vollmer et al.   JOURNAL OF NEUROLOGY

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

(2014) Aaron E Miller et al.   LANCET NEUROLOGY

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model

(2014) Martin Stangel et al.   Therapeutic Advances in Neurological Disorders

Comparison of patient-reported outcome measures in multiple sclerosis

(2013) N. Schäffler et al.   ACTA NEUROLOGICA SCANDINAVICA

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

(2013) Fred D. Lublin et al.   ANNALS OF NEUROLOGY

Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

(2013) Maria Pia Sormani et al.   ANNALS OF NEUROLOGY

Disease-specific molecular events in cortical multiple sclerosis lesions

(2013) Marie Therese Fischer et al.   BRAIN

Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients

(2013) Tjalf Ziemssen et al.   JOURNAL OF NEURAL TRANSMISSION

Brain atrophy and lesion load predict long term disability in multiple sclerosis

(2013) Veronica Popescu et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Efficacy of subcutaneous interferon  -1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes

(2013) N. De Stefano et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Refining response to treatment as defined by the Modified Rio Score

(2013) MP Sormani et al.   Multiple Sclerosis Journal

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes

(2013) Angela Vidal-Jordana et al.   Multiple Sclerosis Journal

Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis

(2013) Luca Prosperini et al.   Multiple Sclerosis Journal

The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients

(2013) Özgür Yaldizli et al.   Multiple Sclerosis Journal

Defining and scoring response to IFN-β in multiple sclerosis

(2013) Maria Pia Sormani et al.   Nature Reviews Neurology

Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis

(2013) Robert Zivadinov et al.   RADIOLOGY

Magnetic resonance monitoring of lesion evolution in multiple sclerosis

(2013) Àlex Rovira et al.   Therapeutic Advances in Neurological Disorders

Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta

(2012) Robert A. Bermel et al.   ANNALS OF NEUROLOGY

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects

(2012) Jeffrey A Cohen et al.   LANCET NEUROLOGY

Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome

(2012) Giancarlo Comi et al.   Multiple Sclerosis Journal

Scoring treatment response in patients with relapsing multiple sclerosis

(2012) MP Sormani et al.   Multiple Sclerosis Journal

Survival in MS

(2012) D.S. Goodin et al.   NEUROLOGY

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis

(2012) Giancarlo Comi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes

(2011) R. Philip Kinkel   ARCHIVES OF NEUROLOGY

Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?

(2011) Luca Prosperini et al.   BMC Neurology

Multiple sclerosis: current treatment algorithms

(2011) Jordi Río et al.   CURRENT OPINION IN NEUROLOGY

Cost of disorders of the brain in Europe 2010

(2011) Anders Gustavsson et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada

(2011) E Kingwell et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis

(2011) Douglas S Goodin et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

(2011) Bhupendra Khatri et al.   LANCET NEUROLOGY

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

(2011) Giancarlo Comi et al.   LANCET NEUROLOGY

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials

(2011) Frederik Barkhof et al.   Nature Reviews Neurology

A critical appraisal of treatment decisions in multiple sclerosis—old versus new

(2011) Bernd C. Kieseier et al.   Nature Reviews Neurology

Consenso español sobre la utilización de natalizumab (Tysabri®) - 2011

(2011) O. Fernández et al.   NEUROLOGIA

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy

(2011) Tamara Castillo-Trivino et al.   PLoS One

Evidence for a two-stage disability progression in multiple sclerosis

(2010) E. Leray et al.   BRAIN

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

(2010) Antonio Scalfari et al.   BRAIN

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

(2010) Ernst-Wilhelm Radue et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes

(2010) N. De Stefano et al.   NEUROLOGY

Ibudilast in relapsing-remitting multiple sclerosis: A neuroprotectant?

(2010) F. Barkhof et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Maximising therapeutic outcomes in patients failing on current therapy

(2009) Christina Caon   JOURNAL OF THE NEUROLOGICAL SCIENCES

Multiple sclerosis beyond EDSS: depression and fatigue

(2009) Tjalf Ziemssen   JOURNAL OF THE NEUROLOGICAL SCIENCES

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

(2009) Ludwig Kappos et al.   LANCET NEUROLOGY

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Social consequences of multiple sclerosis (1): early pension and temporary unemployment—a historical prospective cohort study

(2009) Claudia Christina Hilt Pfleger et al.   Multiple Sclerosis Journal

Measures in the first year of therapy predict the response to interferon β in MS

(2009) J Río et al.   Multiple Sclerosis Journal

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

(2009) Frederik Barkhof et al.   Nature Reviews Neurology

Gray matter atrophy is related to long-term disability in multiple sclerosis

(2008) Leonora K. Fisniku et al.   ANNALS OF NEUROLOGY

Multiple Sclerosis: An Immune or Neurodegenerative Disorder?

(2008) Bruce D. Trapp et al.   Annual Review of Neuroscience

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing–remitting multiple sclerosis in Argentina

(2008) A. Carrá et al.   EUROPEAN JOURNAL OF NEUROLOGY

The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome

(2008) Robert Zivadinov et al.   JOURNAL OF NEUROLOGY

Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations

(2008) et al.   JOURNAL OF NEUROLOGY

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway

(2008) N Grytten Torkildsen et al.   Multiple Sclerosis Journal

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

(2008) J Río et al.   Multiple Sclerosis Journal

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing–remitting multiple sclerosis

(2008) A Gajofatto et al.   Multiple Sclerosis Journal

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

(2008) R. Zivadinov et al.   NEUROLOGY

Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters

(2007) A Minneboo et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Cognitive impairment in different MS subtypes and clinically isolated syndromes

(2007) Constantin Potagas et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES